NCT02960646 - Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 18, 2017

Primary Completion Date

February 13, 2023

Study Completion Date

February 13, 2023

Conditions

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAplastic AnemiaBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveChronic Myelomonocytic LeukemiaChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveLymphoblastic LymphomaMyelodysplastic SyndromeMyeloproliferative NeoplasmPlasma Cell MyelomaRecurrent Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecurrent Hodgkin LymphomaRecurrent Non-Hodgkin LymphomaRecurrent Plasma Cell MyelomaTherapy-Related Myelodysplastic Syndrome

Interventions

DRUG

Cyclophosphamide

Given IV

BIOLOGICAL

Filgrastim

Given SC

DRUG

Fludarabine Phosphate

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Melphalan

Given IV

PROCEDURE

Peripheral Blood Stem Cell Transplantation

Undergo CD45RA depleted peripheral blood stem cell transplantation

BIOLOGICAL

Rituximab

Given IV

DRUG

Tacrolimus

Given IV or PO

RADIATION

Total-Body Irradiation

Undergo TBI

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER